Skip to main content
Erschienen in: Journal of Cancer Survivorship 1/2016

01.02.2016

Incidence of second primary cancers in North Portugal—a population-based study

verfasst von: Luís Pacheco-Figueiredo, Luís Antunes, Maria José Bento, Nuno Lunet

Erschienen in: Journal of Cancer Survivorship | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Longitudinal studies are needed to characterise the burden of second primary malignancies among cancer survivors. Therefore, we quantified the incidence rate and cumulative incidence of second primary cancers (SPC) and standardised incidence ratios (SIR) in a population-based cohort of subjects diagnosed with a first primary cancer (FPC).

Methods

We evaluated a cohort of cancer patients from the Portuguese North Region Cancer Registry (RORENO), with the first diagnosis in 2000–2003 (n = 39451), to estimate the incidence rate and cumulative incidence of SPC and standardised incidence ratios (SIR), for different periods of follow-up, up to 5 years; SPC were defined according to the International Association of Cancer Registries and the International Agency for Research on Cancer guidelines.

Results

The incidence rate of SPC was more than 5-fold higher in the first 2 months of follow-up than in the period between 2 months and 5 years (metachronous SPC), across which the incidence rates were relatively stable. Cancer survivors had an overall higher incidence rate of cancer than the general population (SIR = 1.31 (95 % confidence interval (CI), 1.25–1.38)), although that difference faded when only metachronous SPC were considered (SIR = 1.02 (95 % CI, 0.96–1.08)). Cancer incidence rates were higher among female lung FPC survivors and lower in prostate FPC cancer survivors than in the general population. The 5-year cumulative risk of developing a metachronous SPC was 3.0 % and reached nearly 5.0 % among patients with FPC associated with lower risk of death.

Conclusions

Cancer survivors had higher incident rates of cancer that the general population, especially due to diagnoses in the first months following the FPC. Nevertheless, after this period SPC remain frequent events among cancer survivors.

Implications for cancer survivors

SPC constitute an important dimension of the burden of cancer survivorship, and this needs to be taken into account when defining strategies for surveillance, prevention and counselling.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Araujo F, et al. Trends in cardiovascular diseases and cancer mortality in 45 countries from five continents (1980–2010). Eur J Prev Cardiol. 2013. Araujo F, et al. Trends in cardiovascular diseases and cancer mortality in 45 countries from five continents (1980–2010). Eur J Prev Cardiol. 2013.
2.
Zurück zum Zitat De Angelis R et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):23–34.PubMedCrossRef De Angelis R et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):23–34.PubMedCrossRef
3.
Zurück zum Zitat Ferlay J et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. Lyon: International Agency for Research on Cancer; 2013. Ferlay J et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. Lyon: International Agency for Research on Cancer; 2013.
4.
Zurück zum Zitat Pacheco-Figueiredo L, Lunet N. Health status, use of healthcare, and socio-economic implications of cancer survivorship in Portugal: results from the Fourth National Health Survey. J Cancer Surviv. 2014. Pacheco-Figueiredo L, Lunet N. Health status, use of healthcare, and socio-economic implications of cancer survivorship in Portugal: results from the Fourth National Health Survey. J Cancer Surviv. 2014.
5.
Zurück zum Zitat Curtis R, et al. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute; NIH Publ., 2006. No. 05-5302. Curtis R, et al. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute; NIH Publ., 2006. No. 05-5302.
6.
Zurück zum Zitat Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2020–6.PubMedCrossRef Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2020–6.PubMedCrossRef
7.
8.
Zurück zum Zitat Pacheco-Figueiredo L et al. Evaluation of the frequency of and survival from second primary cancers in North Portugal: a population-based study. Eur J Cancer Prev. 2013;22(6):599–606.PubMedCrossRef Pacheco-Figueiredo L et al. Evaluation of the frequency of and survival from second primary cancers in North Portugal: a population-based study. Eur J Cancer Prev. 2013;22(6):599–606.PubMedCrossRef
9.
Zurück zum Zitat International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev, 2005; 14(4):307–8. International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev, 2005; 14(4):307–8.
10.
Zurück zum Zitat Howe HL. A review of the definition for multiple primary cancers in the United States. Springfield: North American Association of Central Cancer Registries; 2003. Howe HL. A review of the definition for multiple primary cancers in the United States. Springfield: North American Association of Central Cancer Registries; 2003.
11.
Zurück zum Zitat RORENO. Registo Oncologico Regional do Norte. IPO - Porto. 2006. RORENO. Registo Oncologico Regional do Norte. IPO - Porto. 2006.
12.
Zurück zum Zitat Teppo L, Pukkala E, Saxen E. Multiple cancer—an epidemiologic exercise in Finland. J Natl Cancer Inst. 1985;75(2):207–17.PubMed Teppo L, Pukkala E, Saxen E. Multiple cancer—an epidemiologic exercise in Finland. J Natl Cancer Inst. 1985;75(2):207–17.PubMed
13.
Zurück zum Zitat Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer. 2011;11:83.PubMedPubMedCentralCrossRef Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer. 2011;11:83.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Tabuchi T et al. Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data. Cancer Sci. 2012;103(6):1111–20.PubMedCrossRef Tabuchi T et al. Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data. Cancer Sci. 2012;103(6):1111–20.PubMedCrossRef
16.
Zurück zum Zitat Storm HH et al. Multiple primary cancers in Denmark 1943–80; influence of possible underreporting and suggested risk factors. Yale J Biol Med. 1986;59(5):547–59.PubMedPubMedCentral Storm HH et al. Multiple primary cancers in Denmark 1943–80; influence of possible underreporting and suggested risk factors. Yale J Biol Med. 1986;59(5):547–59.PubMedPubMedCentral
17.
Zurück zum Zitat Coleman MP. Multiple primary malignant neoplasms in England and Wales, 1971–1981. Yale J Biol Med. 1986;59(5):517–31.PubMedPubMedCentral Coleman MP. Multiple primary malignant neoplasms in England and Wales, 1971–1981. Yale J Biol Med. 1986;59(5):517–31.PubMedPubMedCentral
18.
Zurück zum Zitat Crocetti E, Buiatti E, Falini P. Multiple primary cancer incidence in Italy. Eur J Cancer. 2001;37(18):2449–56.PubMedCrossRef Crocetti E, Buiatti E, Falini P. Multiple primary cancer incidence in Italy. Eur J Cancer. 2001;37(18):2449–56.PubMedCrossRef
19.
Zurück zum Zitat Liu L et al. Prevalence of multiple malignancies in the Netherlands in 2007. Int J Cancer. 2011;128(7):1659–67.PubMedCrossRef Liu L et al. Prevalence of multiple malignancies in the Netherlands in 2007. Int J Cancer. 2011;128(7):1659–67.PubMedCrossRef
20.
Zurück zum Zitat Nielsen SF, Nordestgaard BG, Bojesen SE. Associations between first and second primary cancers: a population-based study. CMAJ. 2012;184(1):E57–69.PubMedPubMedCentralCrossRef Nielsen SF, Nordestgaard BG, Bojesen SE. Associations between first and second primary cancers: a population-based study. CMAJ. 2012;184(1):E57–69.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Morrison A. Screening in chronic disease. New York: Oxford University Press; 1985. Morrison A. Screening in chronic disease. New York: Oxford University Press; 1985.
22.
Zurück zum Zitat Cancer trends progress report–2011/2012 update. National Cancer Institute, NIH Publ., 2012. Cancer trends progress report–2011/2012 update. National Cancer Institute, NIH Publ., 2012.
23.
Zurück zum Zitat Corkum M et al. Screening for new primary cancers in cancer survivors compared to non-cancer controls: a systematic review and meta-analysis. J Cancer Surviv. 2013;7(3):455–63.PubMedPubMedCentralCrossRef Corkum M et al. Screening for new primary cancers in cancer survivors compared to non-cancer controls: a systematic review and meta-analysis. J Cancer Surviv. 2013;7(3):455–63.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Pacheco-Figueiredo L et al. Health-related behaviours in the EpiPorto study: cancer survivors versus participants with no cancer history. Eur J Cancer Prev. 2011;20(4):348–54.PubMedCrossRef Pacheco-Figueiredo L et al. Health-related behaviours in the EpiPorto study: cancer survivors versus participants with no cancer history. Eur J Cancer Prev. 2011;20(4):348–54.PubMedCrossRef
25.
Zurück zum Zitat Rundle A et al. A prospective study of socioeconomic status, prostate cancer screening and incidence among men at high risk for prostate cancer. Cancer Causes Control. 2013;24(2):297–303.PubMedPubMedCentralCrossRef Rundle A et al. A prospective study of socioeconomic status, prostate cancer screening and incidence among men at high risk for prostate cancer. Cancer Causes Control. 2013;24(2):297–303.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Morgan RM et al. Socioeconomic variation and prostate specific antigen testing in the community: a United Kingdom based population study. J Urol. 2013;190(4):1207–12.PubMedCrossRef Morgan RM et al. Socioeconomic variation and prostate specific antigen testing in the community: a United Kingdom based population study. J Urol. 2013;190(4):1207–12.PubMedCrossRef
27.
28.
Zurück zum Zitat Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94(18):1358–65.PubMedCrossRef Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94(18):1358–65.PubMedCrossRef
29.
Zurück zum Zitat Mavaddat N et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812–22.PubMedCrossRef Mavaddat N et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812–22.PubMedCrossRef
30.
Zurück zum Zitat Dourado F, Carreira H, Lunet N. Mammography use for breast cancer screening in Portugal: results from the 2005/2006 National Health Survey. Eur J Pub Health. 2013;23(3):386–92.CrossRef Dourado F, Carreira H, Lunet N. Mammography use for breast cancer screening in Portugal: results from the 2005/2006 National Health Survey. Eur J Pub Health. 2013;23(3):386–92.CrossRef
31.
32.
Zurück zum Zitat Alves L, Bastos J, Lunet N. Trends in lung cancer mortality in Portugal (1955–2005). Rev Port Pneumol. 2009;15(4):575–87.PubMedCrossRef Alves L, Bastos J, Lunet N. Trends in lung cancer mortality in Portugal (1955–2005). Rev Port Pneumol. 2009;15(4):575–87.PubMedCrossRef
34.
Zurück zum Zitat Castro C et al. Assessing the completeness of cancer registration using suboptimal death certificate information. Eur J Cancer Prev. 2012;21(5):478–9.PubMedCrossRef Castro C et al. Assessing the completeness of cancer registration using suboptimal death certificate information. Eur J Cancer Prev. 2012;21(5):478–9.PubMedCrossRef
35.
Zurück zum Zitat Travis LB et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013;10(5):289–301.PubMedCrossRef Travis LB et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013;10(5):289–301.PubMedCrossRef
Metadaten
Titel
Incidence of second primary cancers in North Portugal—a population-based study
verfasst von
Luís Pacheco-Figueiredo
Luís Antunes
Maria José Bento
Nuno Lunet
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 1/2016
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-015-0460-0

Weitere Artikel der Ausgabe 1/2016

Journal of Cancer Survivorship 1/2016 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.